

ATTD 2017 – PARIS
PRELIMINARY PROGRAM
AS OF 8.8.16

Wednesday, February 15, 2017

12:45-14:15	PARALLEL INDUSTRY WORKSHOP 1	PARALLEL INDUSTRY WORKSHOP 2	PARALLEL INDUSTRY WORKSHOP 3
14:30-16:00	PARALLEL INDUSTRY WORKSHOP 4	PARALLEL INDUSTRY WORKSHOP 5	PARALLEL INDUSTRY WORKSHOP 6
16:15-17:45	PARALLEL INDUSTRY WORKSHOP 7	PARALLEL INDUSTRY WORKSHOP 8	PARALLEL INDUSTRY WORKSHOP 9
18:00-19:30	OPENING CEREMONY (followed by the Networking Reception in the Exhibition Area)		
	Opening Remarks		
	Keynote speaker <u>Eric Renanrd</u> – Moving to a dynamic view of diabetes: a cornerstone on the road toward glucose control		

Thursday, February 16, 2017

08:30-10:00	PLENARY 1 - AUTOMATED CLINICAL DECISION SUPPORT SYSTEMS			
	<u>Aaron Kowalski</u> - Further optimizing diabetes control with Big Data <u>Bruce Bode</u> - Computerized Software using POC Glucose in the Hospital and Outpatient Setting <u>George Grunberger</u> - Challenges and problems in introducing new technologies into clinical practice <u>Moshe Phillip</u> - New Era of personalized treatment of diabetes using decision support tools.			
10:00-10:30	Coffee Break, Exhibition, Posters and E-Posters E-Poster Discussion Sessions 1 – 3			
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM 1			
12:00-13:00	Lunch Break, Exhibition, E-Posters and Posters International Fair of New Technologies in Diabetes			
13:00-14:30	PARALLEL 1 – PREGANANCY AND TECHNOLOGY	PARALLEL 2 - CLOSED-LOOP ALGORITHMS: BENEFITS AND LIMITATIONS OF THE VARIOUS OPTIONS Chairmen: Eric Renard and Hans de Vries	PARALLEL INDUSTRY SYMPOSIUM 1	PARALLEL INDUSTRY WORKSHOP 10
	<u>Yariv Yogeve</u> - The impact of maternal diabetes in pregnancy on future maternal and fetal health <u>Helen Murphy</u> - Adaptability of closed-loop during labor and delivery <u>Moshe Hod</u> - Connecting the Perinatal Hypotheses to the Vicious Cycle of Non Communicable Disease - It all starts in utero	<u>Moshe Phillip/Revital Nimri</u> - Fuzzy logic approach <u>Roman Hovorka</u> - Cambridge's MPC approach <u>Claudio Cobelli</u> - The Italian MPC approach <u>Garry Steil</u> - Harvard's PID approach		
14:30-15:00	Coffee Break, Exhibition, E-Posters and Posters			

15:00-16:30	PLENARY INDUSTRY SYMPOSIUM 2			
16:40-18:00	PARALLEL 3 – TYPE 2 DIABETES AND TECHNOLOGY	PARALLEL 4 - PSYCHOLOGY AND DIABETES TECHNOLOGY Chair: Lori Laffel	PARALLEL INDUSTRY SYMPOSIUM 2	ORAL PRESENTATION SESSION 1
	<u>Walter Pories</u> - The molecular basis for the remission of type 2 diabetes and opportunities for drug development <u>John Pickup</u> - Insulin pump therapy in type 2 diabetes: an individual patient data meta-analysis <u>Irl Hirsch</u> – CGM in type 2 diabetes: Is it a realistic technology? <u>Mark Sperling</u> – Pros and cons of bariatric surgery in adolescents with obesity and T2DM	<u>Lori Laffel</u> - Opportunities to Enhance Technology Use in Pediatric Patients with T1D <u>Katharine Bernard</u> - Making the most of diabetes technology <u>Andrea Scaramuzza</u> - Human factor vs. technology in pediatric diabetes <u>Stephanie Amiel</u> : Psychological tools and education enhancing the awareness of hypoglycemia in diabetic patients		

Friday, February 17, 2017

08:00-08:50	PLENARY INDUSTRY MORNING SYMPOSIUM 3
09:00-10:00	PLENARY 2 - CLOSING THE LOOP Chairmen: Tadej Battelino and Moshe Phillip
	<u>Boris Kovatchev</u> - The International Diabetes Closed-Loop (iDCL) Trial: Progress Report <u>Roman Hovorka</u> - Inpatient glucose control and closed loop insulin delivery <u>Tadej Battelino/Thomas Danne</u> – combine algorithm
10:00-10:30	Coffee Break, Exhibition, Posters and E-Posters E-Poster Discussion Sessions 4 – 6
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM 4
12:00-13:00	Lunch Break, Exhibition, E-Posters and Posters International Fair of New Technologies in Diabetes
13:00-14:30	PLENARY 3 – ATTD 2016 YEARBOOK Chairmen: Moshe Phillip and Tadej Battelino
	<u>Satish Garg/Irl B. Hirsch</u> -Self-monitoring of Blood Glucose <u>Bruce Bode/Tadej Battelino</u> - Continuous Glucose Monitoring <u>John Pickup</u> - Insulin Pumps <u>Eyal Dassau/Revital Nimri</u> - Closing the Loop <u>Jan Bolinder/Thomas Danne/Lutz Heinemann</u> - New Insulins, biosimilars, and Insulin Therapy <u>Neal Kaufman</u> - Using Digital Health Technology to Prevent and Treat Diabetes, <u>Moshe Hod/Helen Murphy</u> - Technology and Pregnancy <u>Desmond Schatz/Natasa Bratina</u> - Immune Intervention for type 1 diabetes, <u>Michael C. Riddell</u> - Advances in Exercise Physical Activity and Diabetes Mellitus, <u>Shlomit Shalitin/David Maahs</u> - Diabetes Technology and Therapy in the Pediatric Age Group <u>Alon Liberman/Bruce Buckingham</u> - Diabetes Technology and the Human Factor <u>Satish Garg</u> - New Medications for the Treatment of Diabetes
14:30-15:00	Coffee Break, Exhibition, Posters and E-Posters

15:00-16:30	PLENARY INDUSTRY SYMPOSIUM 5			
16:40-18:00	PARALLEL 5 – MOVING FORWARD WITH TECHNOLOGY	PARALLEL 6 – NOVEL INSULIN ANALOGUES and ADD-ON THERAPIES IN T1D	PARALLEL 7 – ADVISORS	ORAL PRESENTATION SESSION 2
	<u>Satish Garg</u> – 18-months use of Closed-Loop at home study <u>Eyal Dassau</u> – Implantable AP: Benefits and challenges of IP-IP AP <u>David Maahs</u> – Multiple model probabilistic predictive control: Is a pre-meal bolus necessary? <u>Francis Doyle III</u> – Multi-week outpatient studies with adaptation	<u>Thomas Danne</u> - GLT2 inhibitors as add-on therapy in (pediatric) type 1 diabetes – <u>Chantal Mathieu</u> - New insulins in type 1 diabetes: getting better all the time? <u>Bruce Bode</u> - The use of SGLT-1 and SGLT-2 inhibitors in Type 1 Diabetes <u>Andrej Janež</u> – Add-on therapies in obese pre-diabetic women with polycystic ovary syndrome	Companies dealing with development of advisors who submitted abstract, will be able to present their innovative work in this session.	

Saturday, February 18, 2017

08:00-08:50	PLENARY INDUSTRY MORNING SYMPOSIUM 6			
09:00-10:20	PARALLEL 8 – SPORTS AND DIABETES	PARALLEL 9 – CONNECTED TOOLS: HOW CAN THEY HELP PATIENT DECISIONS ON INSULIN THERAPY? Chairmen: Hans de Vries and Lutz Heinemann	PARALLEL 10 - PRESETAIONS OF START-UP COMPANIES	ORAL PRESENTATION SESSION 3
	<u>Michael Riddell</u> - Physiology and drug development for the prevention of exercise-related hypoglycemia <u>Natasa Bratina</u> – Closed loop and physical activity - a DREAM or already reality? <u>Olga Kordonouri</u> Continuous and Flash Glucose Monitoring in Youth with Type 1 Diabetes Hiking Gorges in Greece and Volcanoes in Island <u>Riccardo Schiaffini</u> - CSII, CGM, and scuba diving in pediatrics	TBD – Unified platform for diabetes management (Glooko Platform) <u>Guillaume Charpentier</u> - The DIABEO platform <u>Marc Breton</u> - CGM-based decision support system combining automated insulin therapy adjustment, smart blousing and hypoglycemia protection in T1D <u>Moshe Phillip/Revital Nimri</u> - Algorithm development for adjusting therapy from data collected from connected tools in patients using SMBG	In this session, start-up companies who won grants will be able to present their innovative work	
10:20-10:50	Coffee Break, Exhibition, Posters and E-Posters			

	PARALLEL 11 - CYBERSECURITY OF MEDICAL DEVICES (DIABETES AND ARTIFICIAL PANCREAS) Chairmen: David Klonoff	PARALLEL 12 - DUAL-HORMONE CLOSED-LOOP: ISSUES AND EXPECTED BENEFITS Chairmen: Lutz Heinemann and Eric Renard	ORAL PRESENTATION SESSION 4	ORAL PRESENTATION SESSION 5
10:50-12:10	<u>David Klonoff</u> - Introduction <u>Eyal Dassau</u> - The Internet of things, Diabetes Management and Automated Insulin Management <u>Harriet Goldman</u> – Novel approaches to cyber security <u>Jay Radcliffe</u> - Are we going too fast? The dangers of connected diabetic devices	<u>Steve Russell</u> - Automated glycemic regulation with a bionic pancreas delivering insulin and glucagon: the Boston approach <u>Ahmad Haidar</u> – Automated glycemic regulation with a dual-hormone (insulin and glucagon) artificial pancreas: the Montreal Approach <u>Stuart Weinzimer</u> - Amylin plus insulin <u>Remi Rabasa-Lhoret</u> - Issues related to infusion of glucagon or amylin		
12:10-13:35	PLENARY 4 – THE EVOLVING FACE OF IMMUNOTHERAPY OF T1D Chairmen: Jay Skyler and <u>Jay Skyler</u> - Introduction <u>Desmond Schatz</u> - Type 1 diabetes biological heterogeneity: Why does it matter? <u>Chantal Mathieu</u> - Lactococcus as a Delivery System for Immunotherapy <u>David Klatzmann</u> - Low dose IL-2 as a Treg stimulator in T1D and beyond <u>Mark Peakman</u> - Antigen-Based Vaccine Therapy for T1D			
13:35-13:45	CLOSING REMARKS AND FAREWELL			
13:45-14:15	Farewell Refreshments in the Exhibition Area			